Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors

AIDS. 2002 Mar 29;16(5):798-9. doi: 10.1097/00002030-200203290-00019.
No abstract available

Publication types

  • Letter

MeSH terms

  • Anti-HIV Agents / pharmacokinetics*
  • Anti-HIV Agents / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • Carbamates
  • Delavirdine / pharmacokinetics*
  • Delavirdine / therapeutic use
  • Drug Synergism
  • Furans
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Protease Inhibitors / pharmacokinetics*
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Lopinavir
  • Pyrimidinones / pharmacokinetics
  • Pyrimidinones / therapeutic use
  • Reverse Transcriptase Inhibitors / pharmacokinetics*
  • Reverse Transcriptase Inhibitors / therapeutic use
  • Ritonavir / pharmacokinetics*
  • Ritonavir / therapeutic use
  • Sulfonamides / pharmacokinetics
  • Sulfonamides / therapeutic use

Substances

  • Anti-HIV Agents
  • Carbamates
  • Furans
  • HIV Protease Inhibitors
  • Pyrimidinones
  • Reverse Transcriptase Inhibitors
  • Sulfonamides
  • Lopinavir
  • amprenavir
  • Delavirdine
  • Ritonavir